Next Phase Newsletter

A Chinese investment group sponsored by the local municipal government manages 2 funds that associated with their local incubator: one USD fund and one RMB fund, and is open to global in-licensing opportunities.

The firm focuses on Class II and Class III medical devices at the development stage, especially prototype-ready projects. The firm pays special attention to companies that are developing projects related to stroke, cardiovascular disease, eye disease, and medical robots. Currently, the firm is not interested in the IVD sector.

The firm prefers companies with a Chinese angle and are open to discuss China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The healthcare and life sciences branch of a large corporation  looks to invest primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic to the firm, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. The firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family-run investment and commercialization vehicle based in the Asia Pacific region invests in early-stage life science and technologies. The group is flexible in terms of deal structure with past investments ranging from minority commitments in a funding round to in-licensing entire therapeutic programs.

The firm specializes in therapeutic opportunities and has a particular focus on rare diseases. The group is most interested in indications where the pathophysiology is well-understood, the developmental pathway is straight-forward, and there is a clear unmet medical need. Opportunities that are de-risked in some way, such as reformulation or repurposing plays, are also attractive to the firm.

The firm has a strong preference for experienced management teams with proven tracks records of driving value.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm with offices in China makes late venture and growth stage investments exclusively in the life sciences. The firm has raised 3 funds to date. The firm recently raised its third fund of USD 200 million in April 2014. The firm’s target investment size is USD 15-20 million per company and typically USD 5 million for cross-border investments. The firm primarily focuses on opportunities in China; however the firm is also interested in companies abroad that have a strong China angle or China strategy in near term (target market, R&D/manufacturing, sales, etc). The firm is actively seeking new investment opportunities.

The firm seeks to invest in late-stage assets that are on market or close to commercialization. The firm is interested in therapeutics/pharmaceuticals, medical devices, diagnostics, and healthcare services. For therapeutics, the firm will consider small molecules and biologics as well as biosimilars and reformulated drugs. At minimum, the product should be in Phase III of clinical trials. The firm may look at Phase II candidates that have a relatively less complicated clinical trial. For example, the firm will not consider biologics in Phase II. For indications, the firm focuses on products that address a large unmet medical need in China. This includes diabetes, cardiovascular, cerebrovascular, liver, and degenerative diseases. For medical devices, the firm is opportunistic in terms of subsectors. Similar to therapeutics, the firm focuses on indications relevant to China. The firm looks for devices that are very close to market or market approved.

The firm is only interested in companies that have a strong China angle or strategy. The firm typically seeks board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in the USA has invested over 160 startups in deep tech-focused areas such as SaaS, Biotech, AI chips, Fintech, Blockchain, and Semiconductors; with multiple unicorns in the firm’s portfolio. The firm recently closed its fourth fund, of $50M AUM, and is actively seeking investment opportunities across a wide range of industries. Within the Life Science area, the firm is interested in Therapeutics, Med Devices, Digital Health, and Diagnostics. The fund will focus on investing in the US or companies who are interested in entering the US market. On average, the typical size of investment is $0.5 – 1M but the firm also has follow-up investment strategies. The firm seeks to invest in early-stage companies, which Seed to Pre-A round is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and digital healthcare companies. The firm is open to a wide range of technologies including novel techniques. Within Medtech, The firm is strongly interested in robotics, semiconductors, sensors, AI modeling diseases, and telemedicine. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA.

The firm has a preference for companies with a full-time founding team and was founded recently (no more than 10 years). The firm can act as either a lead investor or co-investor depends on applicable cases. If the firm acts as the lead investor, it will seek a board seat or an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Western Europe and USA is investing out of its first fund that makes both seed/venture and growth stage investments ranging from $500k – $20M. The firm typically prefers straight equity investments, but will also consider convertible note financings. The firm has a fairly broad mandate, and invests evenly among enterprise software, fintech, consumer and digital health sectors. The fund’s LPs are large insurance companies, and along with capital, the firm looks to add value by providing portfolio companies direct introductions to these groups to help scale and realize their potential.

The firm plans to have digital health companies make up roughly 25% of its portfolio and will invest in consumer and B2B healthcare IT and tech-enabled health services. It is a requirement that the technology has utility for payers and providers. Some of the firm’s digital health portfolio companies include a behavior change platform that partners with insurers, Accountable Care Organizations (ACO) and Self-insured employers to provide research-based behavioral incentives for members to better manage their chronic conditions.

The firm invests in early-stage companies with annual revenues under $5M as well as growth stage companies with annual revenues exceeding $5M. The firm will consider pre-revenue companies with strong management teams and previously successful entrepreneurs. The firm invests globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare focused arm of a family office is interested in global companies, but is currently more focused on the US, Canada, Europe, and Israel regions. The firm makes investments ranging from $5 – $80 million. The firm is open to both leading and co-investing. The firm prefers investing in companies that have demonstrated clinical data and is currently not limited in the number of investments they plan to make this year.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is agnostic to the types of therapeutics, devices, and diagnostics they look to invest in. The firm is most interested in highly differentiable products that address unmet medical needs. Current portfolio companies include companies involved in cancer care, neurostimulation device, and cardiology device companies.

The firm looks for experienced management teams and depending on the deal, may or may not seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.